Ann: First Patient Treated in Phase 2 GvHD Trial, page-34

1. "There’s no office in the USA, how have Cynata managed to recruit a patient over there??! That’s step one in your process, after all. I marked it down and you were still wrong." Show me where CYP has stated the candidate was enrolled in the USA? This is yet another example of CYP shareholder observational skills.
2. As previous, let's not crow until the trial is finished. Remember the MEND trial. Or have you erased it from your mind?
3. "If you actually trawled through MSB’s finances (spoiler alert: you didn’t), care to explain how they torched $230M USD to jab about 10 bums, while Cynata have spent about $20M to treat over 350 patients across the world?". FDA trials vs trials that are not FDA and it's about commercialisation, NOT, number of candidates, and MSB has dosed a lot more candidates across multiple P1, P2 and P3 trials (all FDA - refer previous point). When/if CYP gets there, we can compare notes - until then, you are only making sense to yourself. You do realise that the two companies are at different stages wrt to commercialisation, yeah?
4. You are all Hector's to me. You'all amuse me with your 'knowledge'. It's a bit of fun to me.